Blue Crest Capital Management LTD Alaunos Therapeutics, Inc. Transaction History

Blue Crest Capital Management LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$3.95 - $5.35 $72,399 - $98,060	-18,329 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$4.13 - $6.94 $75,698 - $127,203	18,329 New	18,329 $78,000
Q2 2019 Aug 14, 2019	SELL	$3.98 - $6.2 $93,760 - $146,059	-23,558 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.0 - $4.4 $47,116 - $103,655	23,558 New	23,558 $91,000
Q4 2018 Feb 14, 2019	SELL	$1.61 - $3.62 $19,703 - $44,301	-12,238 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$2.26 - $3.27 $4,040 - $5,846	1,788 Added 17.11%	12,238 $39,000
Q2 2018 Aug 14, 2018	BUY	$3.02 - $4.94 $31,559 - $51,623	10,450 New	10,450 $32,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $424M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

Stay updated on Blue Crest Capital Management LTD with notifications on news.